Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

660.63
Delayed Data
As of May 20
 +3.99 / +0.61%
Today’s Change
492.13
Today|||52-Week Range
747.42
+4.61%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$72.6B

Company Description

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Contact Information

Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown New York 10591-6707
P:(914) 847-7000
Investor Relations:
(914) 847-3482

Employees

Shareholders

Mutual fund holders59.46%
Other institutional29.09%
Individual stakeholders24.52%

Top Executives

Leonard S. SchleiferCo-President, Chief Executive Officer & Director
George Damis YancopoulosCo-President, Director & Chief Scientific Officer
Patrice GiloolySenior VP-Quality Assurance & Operations
Robert E. LandryChief Financial Officer & Executive VP-Finance
Neil StahlExecutive VP-Research & Development